Ascentage Pharma Advances Global Phase III Trial of Lisaftoclax for Higher-Risk MDS with FDA, EMA, and China CDE Clearance
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company headquartered in Suzhou, has received clearance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to begin a registrational Phase III clinical trial of lisaftoclax (APG-2575) for the first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS). The trial, known as GLORA-4 […]